Skip to main content
S 3432 116th Congress Senate Health Advanced technology and technological innovations Congressional oversight Drug safety, medical device, and laboratory regulation Educational facilities and institutions Emergency medical services and trauma care Government information and archives Health technology, devices, supplies Higher education Manufacturing Medical research Prescription drugs Research and development Technology assessment

Securing America’s Medicine Cabinet Act of 2020

Introduced: March 10, 2020 Introduced by: Blackburn, Marsha Republican · Tennessee See on congress.gov
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 10, 2020
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Mar 10, 2020
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Securing America's Medicine Cabinet Act of 2020

This bill encourages the development and approval of advanced pharmaceutical manufacturing technologies and designates certain university research centers to assist in developing such technologies.

The Food and Drug Administration (FDA) must continue to evaluate and approve new drug manufacturing technologies included in an application for drug approval and expedite the development and implementation of such technologies. The FDA must designate such a technology as an advanced manufacturing technology if it is likely to (1) prevent or resolve a drug shortage, (2) maintain an adequate supply of critical medications for national emergencies, or (3) promote the adoption of innovative approaches to drug design and manufacturing.

The sponsor of such a designated technology must provide the FDA with certain related scientific evidence. After receiving this evidence, if the FDA validates the technology for a proposed use, then the sponsor may use the validated technology across multiple manufacturing product lines within the same use context without obtaining additional FDA validation.

The FDA must designate certain institutions of higher education as National Centers of Excellence in Advanced Pharmaceutical Manufacturing. Among other requirements, such centers must demonstrate the ability to provide federal agencies with technical assistance and to train a future workforce in such technologies.

What's happening now March 10, 2020

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Related & companion bills 1
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). S. 3432: Securing America’s Medicine Cabinet Act of 2020. 116th Congress. Open America. https://openamerica.io/bill/116-S-3432/
MLA
"S. 3432: Securing America’s Medicine Cabinet Act of 2020." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-S-3432/.
Bluebook (legal)
S. 3432, 116th Cong. (2026), https://openamerica.io/bill/116-S-3432/.
Markdown link
[S. 3432: Securing America’s Medicine Cabinet Act of 2020](https://openamerica.io/bill/116-S-3432/)
Report a problem